

## Optimizing Bone Health in Cancer Patients

ACPE#: 204-000-11-409-L01P

Credit Hours: 1.0

Date: Friday, April 15, 2011

Time: 12:00-1:30 pm

Location: St. Charles Convention Center, St. Charles, MO

### Program Description

Improvements in cancer treatment have increased survival and the need for effective interventions to reduce the risk for skeletal-related events including pathologic bone fractures, spinal cord compression, need for surgery or radiation therapy to bone, and hypercalcemia of malignancy. Many cancer therapies cause bone loss, which increases the risk for fractures. Bisphosphonates are useful for treating bone metastases and slowing or preventing cancer treatment-induced bone loss (CTIBL). These drugs also may reduce the risk of recurrence and improve survival in patients with early breast cancer or other solid tumors. RANK-ligand Inhibitors have also been shown to decrease skeletal-related events in patients with bone metastases from solid tumors. Other agents for the treatment of bone metastases are under investigation. Knowledge of the role of bisphosphonates and new and emerging bone-targeted therapies in treating patients with bone metastases or CTIBL will enable pharmacists to take an active role in the management of these patients.

### Learning Objectives

At the conclusion of this knowledge-based activity, pharmacists should be able to

1. Describe the prevalence, morbidity, mortality, and impact on quality of life of skeletal-related events in patients with cancer.
2. Explain normal bone remodeling and the pathogenesis of skeletal-related events in patients with cancer.
3. Discuss the mechanism of action, efficacy, and safety of agents used for treating bone metastases and slowing or preventing cancer treatment-induced bone loss (CTIBL).
4. Recommend a pharmacologic regimen for a patient with bone metastases or CTIBL.
5. Identify new or emerging bone-targeted therapies for patients with bone metastases and describe mechanisms of action and potential roles in improving bone health in cancer patients.

### Continuing Education Information



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 hour (0.1 CEU) of continuing pharmacy education credit (ACPE Activity #204-000-11-409-L01P).

Attendees must complete a Continuing Pharmacy Education Request online and may immediately print their statements of continuing pharmacy education credit at the ASHP Learning Center (<http://ce.ashp.org>).

### Faculty

Rowena N. Schwartz, Pharm.D.  
Director Oncology Pharmacy  
The Johns Hopkins Hospital  
Baltimore, MD

Planned and conducted by ASHP Advantage and supported by an educational grant from Novartis Oncology.